HEALTH OF WOMAN. 2020.9-10(155-156): 60-70; doi 10.1007/s00404-020-05816-8
Attil Louis Major, MD PhD^1,2, Vladimir Dvořák, MD PhD³, Jana Schwarzowa, MD⁴, Ales Skrivanek, MD PhD⁵, Tomáš Malik, MD⁶, Marek Pluta, MD, PhD⁷, Ivanna Mayboroda, MD⁸, Etienne Marc Grandjean, MD^9,10
1 Femina Gynaecology Centre, Geneva, Switzerland
² Cantonal Hospital, Department of Obstetrics & Gynecology, University of Fribourg, Switzerland
³ Centrum ambulantni gynekologie a primární péče, s.r.p., Brno, Czech Republic
⁴ Smetanova 388, 252 64 Velké Prilepy, Prague-West, Czech Republic
⁵ G-CENTRUM Olomouc, s.r.o. Olomouc, Czech Republic
⁶ Gyneko spol, s.r.o., Vsetin, Czech Republic
⁷ Faktulni nemocnice v Motole (University Hospital Motol) Onkogynekologická a kolposkopická ambulance, Praha, Czech Republic
⁸ University Hospital of Geneva, Department of Obstetrics & Gynecology, Swityerland
⁹ Phidalsa Pharma-Consultants, Petit-Lancy/Geneva, Switzerland
¹⁰ Camara-Partners, Consultant, Nyon, Switzerland

Journal: Archives of Gynecology and Obstetrics,дата публикации 20.11.2020

СПИСОК ЛИТЕРАТУРЫ

1. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L (2004) Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 291:2100-2106.

2. Connor JP, Elam G, Goldberg JM (2002) Empiric vaginal metronidazole in the management of the ASCUS Papanicolaou smear: a randomized controlled trial. Obstet Gynecol 99:183-187.

3. Ferrante JM, Mayhew DY, Goldberg S, Woodard L, Selleck C, Roetzheim RG (2002) Empiric treatment of minimally abnormal papanicolaou smears with 0.75% metronidazole vaginal gel. J Am Board Fam Pract 15:347-354.

4. Holmes MM, Weaver SH 2nd, Vermillion ST (1999) A randomized, double-blind, placebocontrolled trial of 5-fluorouracil for the treatment of cervicovaginal human papillomavirus. Infect Dis Obstet Gynecol 7:186-189.

5. Frost L, Skajaa K, Hvidman LE, Fay SJ, Larsen PM (1990) No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia. Br J Obstet Gynaecol 97:626-630.

6. Andrejevic-Blant S, Major A, Lüdicke F, Ballini JP, Wagnières G, van den Bergh H, Pelte MF (2004) Time-dependent hexaminolaevulinate induced protoporphyrin IX distribution after topical application in patients with cervical intraepithelial neoplasia: A fluorescence microscopy study. Lasers Surg Med 35:276-283.

7. Hillemanns P, Garcia F, Petry KU, Dvorak V, Sadovsky O, Iversen OE, Einstein MH (2015) A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. Am J Obstet Gynecol 212:465.e1-7. https://doi.org.10.1016/j.ajog.2014.10.1107

8. Geisler S, Speiser S, Speiser L, Heinze G, Rosenthal A, Speiser P (2016) Short-Term Efficacy of Trichloroacetic Acid in the Treatment of Cervical Intraepithelial Neoplasia. Obstet Gynecol 127:353-359. https://doi.org.10.1097/AOG.0000000000001244

9. Rezwan K, Meier LP, Gauckler LJ (2005) Lysozyme and bovine serum albumin adsorption on uncoated silica and AlOOH-coated silica particles: the influence of positively and negatively charged oxide surface coatings. Biomaterials 26:4351-4357.

10. Barrett EG, Johnston C, Oberdorster G, Finkelstein, J N (1999) Silica binds serum proteins resulting in a shift of the dose-response for silica-induced chemokine expression in an alveolar type II cell line. Toxicol Appl Pharmacol 161:111-122.

11. Murray JP, Laband SJ (1979) Degradation of poliovirus by adsorption on inorganic surfaces. Appl Environ Microbiol 37:480-486.

12. Gordienko AS, Kurdish IK (2007). [Electrical properties and interaction with silicon dioxide particles of Bacillus subtilis cells]. Biofizika 52:314-317.

13. Kuklinski B, Kössler P, Fuchs N Use of Selenite-Containing Compounds to be topically or buccally administered. European Patent Office, EP No. 1 450 825 B1, published 13.08.2008; WO2003047604A, WIPO (PCT) International application.

14. Chen Wongworawat Y, Filippova M, Williams VM, Filippov V, Duerksen-Hughes PJ (2016) Chronic oxidative stress increases the integration frequency of foreign DNA and human papillomavirus 16 in human keratinocytes. Am J Cancer Res 6:764-780.

15. Sgambato A, Zannoni GF, Faraglia B, Camerini A, Tarquini E, Spada D, Cittadini A (2004) Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. Gynecol Oncol 92:776-783.

16. Huber J, Pцtsch B, Gantschacher M, Templ M (2016) Routine Treatment of Cervical Cytological Cell Changes: Diagnostic Standard, Prevention and Routine Treatment of Cervical Cytological Cell Changes — An Assessment of Primary and Secondary Prevention and Routine Treatment Data in the Context of an Anonymous Data Collection from Practicing Gynaecologists; an Academic, Non-Interventional Study. Geburtshilfe Frauenheilkd 76:1086-1091.

17. Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, Castle PE, Schiffman M, Kingery JD, Grewal KK, Locke A, Kinney W, Lorey TS (2019) Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. JAMA Intern Med 179: 881–888.

18. Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, Stoler MH, Ronnett BM, Joste NE, Darragh TM, Gravitt PE, Schiffman M, Hunt WC, Kinney WK, Wheeler CM (2019) Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Arch Pathol Lab Med https://doi: 10.5858/arpa.2019-0241-OA.

19. Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N (2019) Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncol 5:181-186.

20. Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS (2018) Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 320:687-705.

21. Negri G, Vittadello F, Romano F, Kasal A, Rivasi F, Girlando S, Mian C, Egarter- Vigl E (2004) P16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 445:616–620.

22. Zhang X, Shen D (2018) p16INK4a and Ki-67 measurement predict progression of cervical low-grade squamous intraepithelial lesion. Int J Clin Exp Pathol 11:4109-4116.

23. del Pino M, Garcia S, Fusté V, Alonso I, Fusté P, Torné A, Ordi J (2009) Value of p16INK4a as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 201:488.e1-7. https://doi.org/10.1016/j.ajog.2009.05.046

24. da Costa LB, Triglia Rde M, França Junior MC, Andrade LA (2015) p16(INK) (4a) expression as a potential marker of low-grade cervical intraepithelial neoplasia progression. APMIS 123:185-189.

25. Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK (2013) Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J Low Genit Tract Dis 17(5Suppl 1):S69-77.

26. Kalof AN, Evans MF, Simmons-Arnold L, Beatty BG, Cooper K (2005) p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol 29:674-679.

27. Benevolo M, Mottolese M, Marandino F, Vocaturo G, Sindico R, Piperno G, Mariani L, Sperduti I, Canalini P, Donnorso RP, Vocaturo A (2006) Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 19:384-391.

28. Donnez J (2020) An update on uterine cervix pathologies related to infertility. Fertil Steril 113:683-684.

29. Sidhu HK, Price JH, McCarron PA, McCafferty DF, Woolfson AD, Biggart D, Thompson W (1997) A randomised controlled trial evaluating a novel cytotoxic drug delivery system for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 104:145–149.

30. Rahangdale L, Lippmann QK, Garcia K, Budwit D, Smith JS, van Le L (2014) Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. Am J Obstet Gynecol 210:314.e1-314.e8.

31. Georgiev D, Karag’ozov I, Velev M, Makaveeva V (2006) [Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions]. Akush Ginekol (Sofiia) 45:59-61.

32. Ashrafian L, Sukhikh G, Kiselev V, Paltsev M, Drukh V, Kuznetsov I, Muyzhnek E, Apolikhina I, Andrianova E (2015) Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention. EPMA J 6:25.

33. Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, Vanden Houte K, Reynders M, Snoeck R, Bossens M (2009) Topical treatment of CIN2+ by cidofovir: results of a phase II, double-blind, prospective, placebo controlled study. Gynecol Oncol 115:69–74.

34. Grimm C, Polterauer S, Natter C, Rahhal J, Hefler L, Tempfer CB, Georg Heinze G, Stary G, Reinthaller A, Paul Speiser P (2012) Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol 120:152–159.

35. Wouters T, Hendriks N, Koeneman M, Kruse A-J, van de Sande A, van Beekhuizen HJ, Gerestein KG, Bekkers RLM, Jurgen M.J. Piek JMJ (2019) Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia – A case series. Case Rep Womens Health 21: e00105. https://doi.org: 10.1016/j.crwh.2019.e00105

36. Koeneman MM, Kruse AJ, Kooreman LF, Zur Hausen A, Hopman AH, Sep SJ, Van Gorp T, Slangen BF, van Beekhuizen HJ, van de Sande AJ, Gerestein CG, Nijman HW, Kruitwagen RF (2017) Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial. BMC Cancer 17:110.

37. Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N (2020) The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG 127:171-180.